Eloralintide d’Eli Lilly passe en phase 3 après des résultats prometteurs en matière de perte de poids Principaux renseignements Eli Lilly va passer le mois prochain à la phase finale des essais cliniques de son médicament expérimental contre l’obésité à base d’amyline, l’eloralinide. Cette décision fait suite aux résultats prometteurs d’une étude intermédiaire. Dans cette étude, l’injection hebdomadaire a entraîné une perte de poids significative chez les participants en surpoids et obèses. […]

Eloralintide d’Eli Lilly passe en phase 3 après des résultats prometteurs en matière de perte de poids #Eloralintide #EliLilly #PerteDePoids #Obésité #Santé

Figure 2. Change in bodyweight (A) Mean percent change in bodyweight from baseline to week 48, shown as observed means and bars indicating SEs. The model-based estimates of the mean percent change in bodyweight and differences among treatment groups at week 48 with the corresponding p values (efficacy estimand only) and 95% CIs are shown in (B) (efficacy estimand) and (D) (treatment-regimen estimand); bars indicate SEs. Multiplicity adjustment was not performed, and p values should be interpreted as exploratory. (C) shows the percentage of participants with bodyweight reductions of at least 5%, 10%, 15%, 20%, 25%, and 30% from baseline to week 48. The percentage of participants is annotated above each bar, calculated with the use of Rubin's rules by combining the percentages of participants who met the thresholds in imputed datasets. *The model-based estimates and 95% CIs from a mixed model repeated measures analysis for the efficacy estimand are shown on the right, denoted by 48.

Eli Lilly continuing to hit it out the park

Selective amylin agonist as an alternative to GLP1RAs? #eloralintide

www.thelancet.com/journals/lan... in @thelancet.com

(Yeah I know it’s #KidneyWk but what do we do till Houston wakes up!)

cc @rnflex.bsky.social

Eli Lilly's Eloralintide Shows Promise for Weight Loss in Obese Adults Eli Lilly's new drug, eloralintide, reveals significant weight loss and good tolerability in Phase 2 trials for adults with obesity, paving the way for further studies.

Eli Lilly's Eloralintide Shows Promise for Weight Loss in Obese Adults #USA #Indianapolis #Eli_Lilly #Obesity_Treatment #eloralintide